OptiScan Biomedical pulled in $2.6 million in new funding, according to a regulatory filing. The Hayward, CA, company makes non-invasive bedside glucose monitoring devices for the hospital intensive care unit. OptiScan's SEC filing does not disclose specific investors involved or for what purpose the money will be used. But OptiScan's website notes that the company will expand the ability of its glucose monitoring devices to detect "additional analytes within the same blood sample." SEC Filing